| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
1-Methylhistamine is a selective agonist of the histamine H3 receptor (Kᵢ = 23 nM for H4 as well), with potency relative to histamine of 81% at H1, 185% at H2, and 270% at H3. It is a key modulator of neurotransmitter release in the CNS and PNS, acting as a presynaptic autoreceptor. It is also a metabolite of histamine. |
|---|---|
| ln Vitro |
1-Methylhistamine dihydrochloride is the end result of histamine 1-methyltransferase in the metabolic pathway responsible for histidine [1].
In vitro, 1-Methylhistamine induces chemotaxis of eosinophils and mast cells via the H4 receptor. It also modulates neurotransmitter release in brain slices via the H3 receptor (inhibiting release of histamine, acetylcholine, norepinephrine, and dopamine). It is used to study H3/H4 receptor pharmacology. |
| ln Vivo |
In animal studies, 1-Methylhistamine is often administered intracerebroventricularly to rodents to study its effects on memory, locomotion, anxiety, and feeding. It is also used in microdialysis studies to measure histamine release in the brain. It is a valuable tool for studying the role of the H3 receptor in CNS disorders.
|
| Enzyme Assay |
A radioligand binding assay is performed using membranes from cells expressing histamine receptors (e.g., HEK293 cells expressing H3 or H4 receptors). 1-Methylhistamine dihydrochloride is incubated with [3H]-N-alpha-methylhistamine (for H3) or other radioligands. Bound radioactivity is measured by filtration and scintillation counting to determine Kᵢ values.
|
| Cell Assay |
Human eosinophils or dendritic cells are treated with 1-Methylhistamine (0.1-100 microM). Chemotaxis is assessed using a Boyden chamber or microfluidic device. Intracellular calcium mobilization is measured using fluorescent calcium indicators (e.g., Fluo-4) after activation of the H4 receptor (which is Gᵢ-coupled).
|
| Animal Protocol |
In animal studies, 1-Methylhistamine dihydrochloride is typically dissolved in sterile saline or artificial CSF. It is administered to rodents by intracerebroventricular (ICV) injection (5-50 microg) or sometimes by intraperitoneal injection for peripheral effects. Behavioral tests (e.g., open field, Y-maze, forced swim test) are conducted, and brain neurotransmitter levels are measured by microdialysis followed by HPLC.
|
| ADME/Pharmacokinetics |
1-Methylhistamine is a minor histamine metabolite, representing about 5-10% of histamine turnover. Its plasma half-life is short (approximately 20 minutes) due to rapid deamination by monoamine oxidase B (MAO-B) to imidazoleacetic acid. It does cross the blood-brain barrier, but it is rapidly metabolized there as well.
|
| Toxicity/Toxicokinetics |
The compound is not highly toxic, as it is a natural metabolite. High doses may cause mild pruritus, sedation, and hypotension due to H3/H4 receptor activation. The dihydrochloride salt may cause gastrointestinal irritation. No serious organ toxicity has been reported at research doses (ICV administration).
|
| References | |
| Additional Infomation |
1-Methylhistamine dihydrochloride is used as a standard for histamine metabolite analysis by HPLC and LC-MS in clinical diagnostics and metabolomics. It is also a valuable tool compound to study the histamine H3 and H4 receptors in the context of inflammation, allergy, cognitive disorders, and CNS drug discovery. It is not an approved drug.
|
| Molecular Formula |
C6H13CL2N3
|
|---|---|
| Molecular Weight |
198.09
|
| Exact Mass |
161.072
|
| CAS # |
6481-48-7
|
| Related CAS # |
1-Methylhistamine-d3 dihydrochloride;344299-49-6;1-Methylhistamine;501-75-7
|
| PubChem CID |
11957601
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
1.423
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
84.4
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=C(N=C1)CCN.Cl.Cl
|
| InChi Key |
AGXVEALMQHTMSW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H11N3.2ClH/c1-9-4-6(2-3-7)8-5-9;;/h4-5H,2-3,7H2,1H3;2*1H
|
| Chemical Name |
2-(1-methylimidazol-4-yl)ethanamine;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~62.5 mg/mL (~315.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (504.82 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0482 mL | 25.2411 mL | 50.4821 mL | |
| 5 mM | 1.0096 mL | 5.0482 mL | 10.0964 mL | |
| 10 mM | 0.5048 mL | 2.5241 mL | 5.0482 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
